Physician profile
David W Brown
NPI 1710985361
$1,628.68
in general payments reported to CMS, 2019-2025
21 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $121 · 2021: $413 · 2022: $330 · 2023: $102 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $121 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $121.15 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $259.90 | 2019-2023 | Opdualag |
| Novartis Pharmaceuticals Corporation | $166.87 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $150.20 | 2019-2023 | Keytruda |
| Amgen INC. | $148.69 | 2019-2020 | |
| Janssen Biotech, INC. | $128.15 | 2020-2025 | Erleada |
| Lilly USA, LLC | $117.23 | 2019-2022 | |
| Astellas Pharma US INC | $99.54 | 2019-2022 | |
| Clovis Oncology, INC. | $95.00 | 2019 | |
| Seagen INC. | $89.88 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.64 | 2019-2021 | |
| Pfizer INC. | $57.93 | 2019-2021 | |
| Genentech USA, INC. | $43.85 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $32.36 | 2021 | |
| Celgene Corporation | $29.69 | 2022-2023 | Pomalyst |
| Dendreon Pharmaceuticals LLC | $28.89 | 2023 | Provenge |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $23.47 | 2023 | Cosela |
| Regeneron Healthcare Solutions, INC. | $18.91 | 2025 | Libtayo |
| Puma Biotechnology, INC. | $17.06 | 2021 | |
| Fortovia Therapeutics, INC. | $14.50 | 2019 | |
| Blueprint Medicines Corporation | $12.00 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.